PMID- 25072116
OWN - NLM
STAT- MEDLINE
DCOM- 20150723
LR  - 20211021
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Print)
IS  - 0165-2478 (Linking)
VI  - 162
IP  - 1 Pt A
DP  - 2014 Nov
TI  - Targeting human dendritic cells in situ to improve vaccines.
PG  - 59-67
LID - S0165-2478(14)00144-8 [pii]
LID - 10.1016/j.imlet.2014.07.004 [doi]
AB  - Dendritic cells (DCs) provide a critical link between innate and adaptive 
      immunity. The potent antigen presenting properties of DCs makes them a valuable 
      target for the delivery of immunogenic cargo. Recent clinical studies describing 
      in situ DC targeting with antibody-mediated targeting of DC receptor through 
      DEC-205 provide new opportunities for the clinical application of DC-targeted 
      vaccines. Further advances with nanoparticle vectors which can encapsulate 
      antigens and adjuvants within the same compartment and be targeted against 
      diverse DC subsets also represent an attractive strategy for targeting DCs. This 
      review provides a brief summary of the rationale behind targeting dendritic cells 
      in situ, the existing pre-clinical and clinical data on these vaccines and 
      challenges faced by the next generation DC-targeted vaccines.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Sehgal, Kartik
AU  - Sehgal K
AD  - Department of Medicine, Yale University, New Haven, CT, United States.
FAU - Dhodapkar, Kavita M
AU  - Dhodapkar KM
AD  - Pediatrics, Yale University, New Haven, CT, United States.
FAU - Dhodapkar, Madhav V
AU  - Dhodapkar MV
AD  - Department of Medicine, Yale University, New Haven, CT, United States. Electronic 
      address: madhav.dhodapkar@yale.edu.
LA  - eng
GR  - CA135110/CA/NCI NIH HHS/United States
GR  - CA106802/CA/NCI NIH HHS/United States
GR  - R01 CA106802/CA/NCI NIH HHS/United States
GR  - R01 CA109465/CA/NCI NIH HHS/United States
GR  - R01 AI079222/AI/NIAID NIH HHS/United States
GR  - R01 CA156689/CA/NCI NIH HHS/United States
GR  - AI079222/AI/NIAID NIH HHS/United States
GR  - R01 CA135110/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140727
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (Antibodies)
RN  - 0 (Antigens)
RN  - 0 (Vaccines)
SB  - IM
MH  - Animals
MH  - Antibodies/immunology
MH  - Antigen Presentation/immunology
MH  - Antigen-Presenting Cells/immunology/metabolism
MH  - Antigens/immunology
MH  - Dendritic Cells/*immunology/metabolism
MH  - Humans
MH  - Mice
MH  - Nanoparticles
MH  - Phenotype
MH  - Vaccines/*immunology
PMC - PMC4506641
MID - NIHMS616926
OTO - NOTNLM
OT  - Dendritic cell
OT  - Nanoparticles
OT  - Targeted vaccines
EDAT- 2014/07/30 06:00
MHDA- 2015/07/24 06:00
PMCR- 2015/11/01
CRDT- 2014/07/30 06:00
PHST- 2014/07/06 00:00 [received]
PHST- 2014/07/17 00:00 [revised]
PHST- 2014/07/17 00:00 [accepted]
PHST- 2014/07/30 06:00 [entrez]
PHST- 2014/07/30 06:00 [pubmed]
PHST- 2015/07/24 06:00 [medline]
PHST- 2015/11/01 00:00 [pmc-release]
AID - S0165-2478(14)00144-8 [pii]
AID - 10.1016/j.imlet.2014.07.004 [doi]
PST - ppublish
SO  - Immunol Lett. 2014 Nov;162(1 Pt A):59-67. doi: 10.1016/j.imlet.2014.07.004. Epub 
      2014 Jul 27.